Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Survival for Head and Neck Squamous Cell Carcinoma Treated With Versus Without Neoadjuvant Systemic Therapy: A National Propensity Score–Matched Analysis Tumor response was assessed by RECISTv1.1.
Immunotherapies are transforming treatment and improving outcomes for patients with advanced cSCC, according to Todd Schlesinger, MD. In part 1 of the interview, he described how cSCC compares with ...
Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma PD-L1 ...
Cancer immunotherapy has saved lives, but it often falls short due to off-target toxicity and weak tumor-specific immune ...
The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has said no to an application to extend the use of Opdualag (nivolumab/relatlimab, Bristol Myers Squibb) to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results